Innovent Biologics, Inc.
http://www.innoventbio.com/en/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Innovent Biologics, Inc.
Lilly Oncology President Anne White On Loxo Success, What’s To Come
White said the late 2019 creation of Loxo Oncology at Lilly to spearhead cancer R&D has exceeded her expectations. The executive also discussed COVID-19’s impact on drug sales and cancer screening.
As China Prices Drop, Junshi Looks To Coherus To Take PD-1 Global
After Novartis, US firm Coherus leaps into the China immuno-oncology fray by licensing rights to innovative drugs from Shanghai's Junshi.
China Approves Record New Cancer, Orphan Drugs In 2020 But Access Challenges Remain
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?
Innovent Expands Internationally With Indonesia Deal
Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.
Company Information
- Industry
- Pharmaceuticals
- Services
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes
- Other Names / Subsidiaries
-
- Innovent Biologics (Suzhou) Co., Ltd.